Chengdu Hoist Biotechnology

Chengdu Hoist Biotechnology is a clinical-stage biopharmaceutical company based in Chengdu, China, dedicated to the development of innovative immune cell therapies for viral-related cancers and chronic infectious diseases. The company specializes in T cell receptor engineered T cell (TCR-T) therapies, leveraging a proprietary platform to identify and optimize high-affinity TCRs that target specific viral antigens. Its lead candidate, HS-IT001, is an autologous TCR-T therapy designed to treat Hepatitis B virus (HBV)-related hepatocellular carcinoma by recognizing HBV antigens presented on tumor cells. Hoist Biotechnology aims to address the significant clinical burden of liver cancer in the Asia-Pacific region through its advanced cell engineering capabilities. The company's pipeline also includes CAR-T and other TCR-T programs targeting various solid tumors.